News coverage about Pulmatrix (NASDAQ:PULM) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pulmatrix earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 47.7431240724191 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
PULM has been the subject of a number of research reports. HC Wainwright decreased their target price on Pulmatrix to $3.00 and set a “buy” rating for the company in a report on Friday, March 16th. ValuEngine raised Pulmatrix from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
NASDAQ PULM traded down $0.04 during trading hours on Monday, hitting $0.46. The company had a trading volume of 1,819,208 shares, compared to its average volume of 656,617. Pulmatrix has a fifty-two week low of $0.45 and a fifty-two week high of $3.42. The firm has a market capitalization of $19.35, a PE ratio of -0.49 and a beta of 2.74.
TRADEMARK VIOLATION NOTICE: This report was first posted by Week Herald and is owned by of Week Herald. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://weekherald.com/2018/04/16/pulmatrix-pulm-receiving-somewhat-positive-media-coverage-report-shows.html.
Pulmatrix, Inc, a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. The company's proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis (IPF).
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.